Overview

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.
Phase:
Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Cyclophosphamide
Interleukin-2